Tearsheet

Fonar (FONR)


Market Price (12/29/2025): $14.48 | Market Cap: $89.3 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Fonar (FONR)


Market Price (12/29/2025): $14.48
Market Cap: $89.3 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.


0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.2%, FCF Yield is 8.3%
Weak multi-year price returns
2Y Excs Rtn is -75%, 3Y Excs Rtn is -95%
Key risks
FONR key risks include [1] a declining equipment business facing intense competition from larger players and [2] profit deterioration driven by rising operational costs and increased insurance carrier risk.
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16%
  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11%
  
3 Low stock price volatility
Vol 12M is 29%
  
4 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, Precision Medicine, and Medical Devices. Themes include Advanced Diagnostics, Show more.
  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.2%, FCF Yield is 8.3%
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11%
3 Low stock price volatility
Vol 12M is 29%
4 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, Precision Medicine, and Medical Devices. Themes include Advanced Diagnostics, Show more.
5 Weak multi-year price returns
2Y Excs Rtn is -75%, 3Y Excs Rtn is -95%
6 Key risks
FONR key risks include [1] a declining equipment business facing intense competition from larger players and [2] profit deterioration driven by rising operational costs and increased insurance carrier risk.

Valuation, Metrics & Events

FONR Stock


Why The Stock Moved


Qualitative Assessment

AI Analysis | Feedback

Here are key points explaining the negative movement in Fonar (FONR) stock for the approximate time period from August 31, 2025, to December 29, 2025:

1. Declining Profitability in Fiscal Year 2025 and Q1 Fiscal 2026

Fonar reported a decrease in income from operations, net income, and diluted earnings per share for fiscal year 2025 (ended June 30, 2025), with income from operations decreasing 30% to $11.6 million and net income decreasing 24% to $10.7 million. This trend continued into the first quarter of fiscal 2026 (ended September 30, 2025), where net income attributable to Fonar declined from $3.135 million to $2.264 million and income from operations fell to $3.194 million.

2. Increased Operating Costs and Expenses

Total costs and expenses for fiscal year 2025 increased by 7% to $92.8 million compared to the previous fiscal year, leading to compressed margins despite a slight increase in total revenues. This rise in expenses put pressure on the company's overall profitability.

Show more

Stock Movement Drivers

Fundamental Drivers

The -5.9% change in FONR stock from 9/28/2025 to 12/28/2025 was primarily driven by a -11.4% change in the company's Net Income Margin (%).
928202512282025Change
Stock Price ($)15.3614.45-5.92%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)104.35105.431.04%
Net Income Margin (%)7.99%7.08%-11.37%
P/E Multiple11.2611.946.04%
Shares Outstanding (Mil)6.116.17-0.94%
Cumulative Contribution-5.93%

LTM = Last Twelve Months as of date shown

Market Drivers

9/28/2025 to 12/28/2025
ReturnCorrelation
FONR-5.9% 
Market (SPY)4.3%3.2%
Sector (XLV)15.2%31.4%

Fundamental Drivers

The -2.9% change in FONR stock from 6/29/2025 to 12/28/2025 was primarily driven by a -13.6% change in the company's Net Income Margin (%).
629202512282025Change
Stock Price ($)14.8814.45-2.89%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)103.02105.432.35%
Net Income Margin (%)8.19%7.08%-13.55%
P/E Multiple10.8811.949.78%
Shares Outstanding (Mil)6.176.17-0.02%
Cumulative Contribution-2.89%

LTM = Last Twelve Months as of date shown

Market Drivers

6/29/2025 to 12/28/2025
ReturnCorrelation
FONR-2.9% 
Market (SPY)12.6%2.3%
Sector (XLV)17.0%25.1%

Fundamental Drivers

The -3.3% change in FONR stock from 12/28/2024 to 12/28/2025 was primarily driven by a -24.8% change in the company's Net Income Margin (%).
1228202412282025Change
Stock Price ($)14.9514.45-3.34%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)102.01105.433.36%
Net Income Margin (%)9.41%7.08%-24.76%
P/E Multiple9.8211.9421.62%
Shares Outstanding (Mil)6.306.172.14%
Cumulative Contribution-3.39%

LTM = Last Twelve Months as of date shown

Market Drivers

12/28/2024 to 12/28/2025
ReturnCorrelation
FONR-3.3% 
Market (SPY)17.0%10.6%
Sector (XLV)13.8%23.4%

Fundamental Drivers

The -16.0% change in FONR stock from 12/29/2022 to 12/28/2025 was primarily driven by a -35.2% change in the company's Net Income Margin (%).
1229202212282025Change
Stock Price ($)17.2114.45-16.04%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)97.05105.438.64%
Net Income Margin (%)10.92%7.08%-35.19%
P/E Multiple10.6311.9412.41%
Shares Outstanding (Mil)6.546.175.74%
Cumulative Contribution-16.31%

LTM = Last Twelve Months as of date shown

Market Drivers

12/29/2023 to 12/28/2025
ReturnCorrelation
FONR-26.1% 
Market (SPY)48.4%14.4%
Sector (XLV)17.8%20.0%

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
FONR Return-12%-14%12%17%-23%-4%-26%
Peers Return16%38%-12%21%26%16%150%
S&P 500 Return16%27%-19%24%23%18%114%

Monthly Win Rates [3]
FONR Win Rate42%50%50%33%33%58% 
Peers Win Rate52%65%42%68%57%52% 
S&P 500 Win Rate58%75%42%67%75%73% 

Max Drawdowns [4]
FONR Max Drawdown-43%-16%-11%-25%-26%-21% 
Peers Max Drawdown-34%-5%-26%-7%-9%-23% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)

How Low Can It Go

Unique KeyEventFONRS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-38.5%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven62.5%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven54 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-48.0%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven92.1%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven66 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-42.9%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven75.0%24.7%
2018 CorrectionTime to BreakevenTime to BreakevenNot Fully Recovered days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-92.3%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven1191.0%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1,673 days1,480 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

Fonar's stock fell -38.5% during the 2022 Inflation Shock from a high on 3/11/2021. A -38.5% loss requires a 62.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Fonar (FONR)

FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates through two segments, Medical Equipment segment, and Physician Management and Diagnostic services segment. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters and the development and implementation of practice growth and marketing strategies. The company owns and operates 5 diagnostic imaging facilities in Florida; and manages 39 MRI scanning facilities, including 25 facilities located in New York and 14 situated in Florida. It markets its scanners to private diagnostic imaging centers and hospitals. The company was incorporated in 1978 and is based in Melville, New York.

AI Analysis | Feedback

Here are 1-2 brief analogies for Fonar (FONR):

  • Like Intuitive Surgical (makers of da Vinci surgical robots), but focused on specialized diagnostic imaging with unique Upright MRI technology.
  • The GE Healthcare or Siemens Healthineers of specialized Upright MRI scanning.

AI Analysis | Feedback

  • Upright® Multi-Positionâ„¢ MRI: This innovative magnetic resonance imaging scanner allows patients to be scanned in various weight-bearing, multi-position configurations, including standing, sitting, or bending, to visualize conditions not apparent in traditional lie-down MRIs.

AI Analysis | Feedback

Fonar Corporation (NASDAQ: FONR) primarily sells its medical equipment, specifically its Upright® Multi-Position™ MRI scanners, to other companies and institutions.

While Fonar's business model involves selling to other companies, the company does not publicly disclose the specific names of its individual major customers (such as specific hospitals, imaging centers, or physician groups) in its SEC filings or press releases. This is a common practice for manufacturers of high-value capital medical equipment, often due to confidentiality agreements and competitive considerations.

However, Fonar's public disclosures, including its 10-K filings, describe the categories of its B2B customers for the Medical Equipment segment. These categories include:

  • Private diagnostic imaging centers
  • Hospitals
  • Private physician practices
  • Government facilities (both domestic and international)

Additionally, Fonar operates a Diagnostic Imaging Management segment through its subsidiary, Health Management Corporation of America (HMCA), which manages diagnostic imaging centers. While these managed centers provide services directly to individual patients, Fonar's customers in its Medical Equipment segment are the entities that purchase its MRI machines.

AI Analysis | Feedback

null

AI Analysis | Feedback

Timothy R. Damadian

Chief Executive Officer and President

Timothy R. Damadian has served as Chief Executive Officer and President of FONAR Corporation since February 11, 2016. He began his career at FONAR in 1985, installing magnets, shielded rooms, and electronics, eventually becoming Vice President of Operations. In 1997, Mr. Damadian formed Health Management Corporation of America (HMCA), a wholly-owned subsidiary of FONAR, where he served as President and managed numerous medical and diagnostic imaging offices. He left FONAR in 2001 to establish Integrity Healthcare Management, Inc., a diagnostic imaging management company that managed 11 MRI scanning centers in New York and Florida. Integrity Healthcare Management, Inc. was successfully sold to Health Diagnostics in 2007. Mr. Damadian returned to FONAR as a consultant in 2010.

Raymond V. Damadian, M.D.

Chairman of the Board, Principal Financial Officer & Treasurer

Dr. Raymond V. Damadian is the founder of FONAR Corporation, incorporated in 1978. He is recognized as the inventor of the MRI scanner and performed the first full-body human scan in 1977. Dr. Damadian served as President of Fonar Corp. since its inception and as Chief Executive Officer until February 11, 2016. He has also served as the company's Principal Financial Officer and Treasurer since February 2001. In addition to his roles at FONAR, he serves as President and Treasurer of Health Management Corporation of America (HMCA), a FONAR subsidiary. Dr. Damadian holds a B.S. in Mathematics from the University of Wisconsin (1956) and an M.D. from Albert Einstein College of Medicine (1960), and conducted post-graduate work in physics, mathematics, and electronics at Harvard University. His pioneering work earned him the National Medal of Technology in 1988 and induction into the National Inventors Hall of Fame in 1989.

Luciano B. Bonanni

Chief Operating Officer & Executive Vice President

Luciano B. Bonanni has served as Chief Operating Officer and Executive Vice President of Fonar Corp. since June 27, 2016. Prior to this, Mr. Bonanni served as Vice President of Fonar Corp. since 1989. In his tenure as Vice President, he was responsible for overseeing a wide range of operations, including general operations, research and development, manufacturing, service, sales, finance, accounting, and regulatory compliance.

AI Analysis | Feedback

Key Risks to Fonar (FONR) Business:
  1. Declining equipment business and intense competition from larger players pose a significant threat to Fonar's long-term growth and market position. The company's machine sales have substantially decreased over the years, and it faces competition from larger firms with greater resources for research, development, and marketing, such as GE, Siemens, and Toshiba.
  2. Fonar has experienced profit deterioration due to rising operational costs and increased insurance carrier risk. Despite modest revenue growth, the company's operating income and net income have seen significant declines, primarily attributed to increased selling, general, and administrative (SG&A) expenses and the need for additional reserves against accounts receivable.
  3. Changes in the healthcare market and declining reimbursement rates present an ongoing risk. The implementation of healthcare policies has led to a reduction in reimbursement rates for MRI centers, which directly impacts the fees received by Fonar. Increased competition within the healthcare sector further influences scan volumes, affecting the company's revenue streams.

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable markets for Fonar's main products and services are primarily within the Magnetic Resonance Imaging (MRI) sector, specifically focusing on their unique Upright® MRI / Stand-Up™ MRI systems and related services.

MRI Scanners (specifically Open and Upright MRI Systems)

Fonar is known for designing, manufacturing, selling, and servicing MRI scanners, particularly their UPRIGHT® MRI, also known as the Stand-Up™ MRI, which allows patients to be scanned in weight-bearing positions. This technology is a type of open MRI.

  • Global MRI Market: The global magnetic resonance imaging market size was valued at approximately USD 7.1 billion in 2024 and is projected to reach USD 10.3 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.5% from 2025 to 2030. Another estimate places the global MRI market at USD 7.55 billion in 2025, with an anticipated growth to USD 13.32 billion by 2034, exhibiting a CAGR of 6.52%. The global MRI systems market is also predicted to reach US$ 10 billion by 2032, with a CAGR of 5.8% during the forecast period.
  • U.S. MRI Market: The U.S. magnetic resonance imaging market size was valued at USD 1.70 billion in 2023 and is anticipated to exceed USD 3.15 billion by 2033, growing at a CAGR of 6.36% from 2023 to 2033. Another report indicates the U.S. market size was USD 2.22 billion in 2024 and is predicted to be worth around USD 3.33 billion by 2034, rising at a CAGR of 4.10% from 2024 to 2034. The U.S. MRI market was valued at USD 1.396 billion in 2025 and is projected to grow at a CAGR of 4.32% through 2030, reaching US$1.846 billion.
  • Open MRI Systems Segment: While specific market sizes for "Upright MRI" are not separately quantified, they fall under the "Open MRI systems" category. The open MRI system segment is estimated to grow at a CAGR of 7.72% globally during the predicted period. In the U.S. market, open MRI systems are showing a high growth rate of 7.6% CAGR.

Physician Management and Diagnostic Services

Fonar, through its subsidiary Health Management Company of America (HMCA), provides non-medical management services to diagnostic imaging facilities and also owns and operates diagnostic imaging facilities. A specific addressable market size for "Physician Management and Diagnostic Services" directly tied to MRI facilities for a company like Fonar is not readily available in the provided search results.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Fonar (FONR) over the next 2-3 years:

  1. Growth in MRI Scan Volumes and Diagnostic Services: Fonar's Health Management Company of America (HMCA) subsidiary, which manages diagnostic imaging centers, is a significant revenue contributor. Chairman and CEO Timothy Damadian highlighted record-setting scan volumes as a key driver of revenue growth, with increases observed both sequentially and year-over-year. This indicates a growing demand for imaging services through their managed network.
  2. Expansion of MRI Scanner Network: The company's growth strategy includes establishing new locations and deploying additional MRI scanners at existing facilities to meet increasing demand. Specific plans include enhancing current facilities in Florida and New York by integrating high-field MRIs, aiming to attract more patient referrals and alleviate appointment backlogs.
  3. Adoption of SwiftMR Technology: The continued adoption of SwiftMR by radiologists and physicians is expected to enhance Fonar's economies of scale. By facilitating faster capital turnover, SwiftMR can improve operational efficiency, potentially leading to increased scan capacity and, consequently, higher revenue.
  4. Leveraging Unique UPRIGHT® Multi-Position™ MRI Capabilities: Fonar's UPRIGHT® Multi-Position™ MRI is unique in its ability to image patients in weight-bearing positions, providing diagnostic information that traditional lie-down scanners cannot. This distinct capability serves as a strong competitive advantage, driving demand and referrals for its specialized imaging services.

AI Analysis | Feedback

Share Repurchases

  • Fonar adopted a stock repurchase plan of up to $9 million on September 13, 2022.
  • As of September 30, 2024, the company had repurchased 283,770 shares at a cost of $4,680,889 under this plan.
  • By the fiscal year ended June 30, 2025, Fonar had repurchased 373,942 shares for $6.1 million under the repurchase plan.

Capital Expenditures

  • Capital expenditures were approximately $3.79 million in fiscal year 2025, $0.79 million in fiscal year 2024, and $4.22 million in fiscal year 2023.
  • Cash used in investing activities amounted to $1.8 million for the quarter ended September 30, 2024.
  • Planned capital expenditures include approximately $2.0 million for the purchase and installation of a new scanner and associated buildout costs in New York. A significant investment was also made in developing the capacity to service third-party MRI equipment through the Opus Diagnostic Services, LLC subsidiary.

Better Bets than Fonar (FONR)

Latest Trefis Analyses

TitleTopic
0DASHBOARDS 
1How Low Can Fonar Stock Really Go?Return
Title
0ARTICLES

Trade Ideas

Select ideas related to FONR. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
21.4%21.4%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-7.4%-7.4%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
18.0%18.0%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
3.9%3.9%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
12.2%12.2%-5.1%

Recent Active Movers

More From Trefis

Peer Comparisons for Fonar

Peers to compare with:

Financials

FONRHPQHPEIBMCSCOAAPLMedian
NameFonar HP Hewlett .Internat.Cisco Sy.Apple  
Mkt Price14.4523.2624.49305.0978.16273.4051.32
Mkt Cap0.121.932.6284.9309.24,074.4158.8
Rev LTM10555,29534,29665,40257,696408,62556,496
Op Inc LTM103,6241,64411,54412,991130,2147,584
FCF LTM72,80062711,85412,73396,1847,327
FCF 3Y Avg102,9781,40011,75313,879100,5037,366
CFO LTM113,6972,91913,48313,744108,5658,590
CFO 3Y Avg133,6723,89613,49814,736111,5598,697

Growth & Margins

FONRHPQHPEIBMCSCOAAPLMedian
NameFonar HP Hewlett .Internat.Cisco Sy.Apple  
Rev Chg LTM3.4%3.2%13.8%4.5%8.9%6.0%5.2%
Rev Chg 3Y Avg2.8%-3.9%6.5%2.6%3.7%1.8%2.7%
Rev Chg Q4.3%4.2%14.4%9.1%7.5%9.6%8.3%
QoQ Delta Rev Chg LTM1.0%1.1%3.7%2.1%1.8%2.1%2.0%
Op Mgn LTM9.7%6.6%4.8%17.7%22.5%31.9%13.7%
Op Mgn 3Y Avg13.7%7.4%7.2%16.4%24.2%30.8%15.0%
QoQ Delta Op Mgn LTM-1.5%-0.2%-1.4%0.6%0.4%0.1%-0.1%
CFO/Rev LTM10.7%6.7%8.5%20.6%23.8%26.6%15.7%
CFO/Rev 3Y Avg12.6%6.8%12.7%21.4%26.1%28.4%17.1%
FCF/Rev LTM7.0%5.1%1.8%18.1%22.1%23.5%12.6%
FCF/Rev 3Y Avg9.4%5.5%4.6%18.6%24.6%25.6%14.0%

Valuation

FONRHPQHPEIBMCSCOAAPLMedian
NameFonar HP Hewlett .Internat.Cisco Sy.Apple  
Mkt Cap0.121.932.6284.9309.24,074.4158.8
P/S0.80.41.04.45.410.02.7
P/EBIT7.36.819.925.122.531.321.2
P/E11.98.6572.736.029.941.033.0
P/CFO7.95.911.221.122.537.516.2
Total Yield8.4%14.1%2.3%5.0%5.4%2.8%5.2%
Dividend Yield0.0%2.5%2.1%2.2%2.1%0.4%2.1%
FCF Yield 3Y Avg9.8%10.6%5.5%6.4%6.0%3.1%6.2%
D/E0.40.50.70.20.10.00.3
Net D/E-0.20.30.60.20.00.00.1

Returns

FONRHPQHPEIBMCSCOAAPLMedian
NameFonar HP Hewlett .Internat.Cisco Sy.Apple  
1M Rtn3.0%-3.6%12.7%-1.1%1.6%-2.0%0.2%
3M Rtn-5.9%-11.9%2.7%7.9%17.0%7.1%4.9%
6M Rtn-2.9%-4.0%34.5%6.6%15.2%36.3%10.9%
12M Rtn-3.3%-27.0%16.2%40.5%34.5%7.5%11.8%
3Y Rtn-16.0%-3.7%67.3%141.3%79.6%114.1%73.5%
1M Excs Rtn-0.7%-5.6%12.9%-2.2%-0.0%-3.7%-1.4%
3M Excs Rtn-10.2%-16.2%-1.7%3.6%12.7%2.8%0.6%
6M Excs Rtn-15.2%-16.3%22.3%-5.7%3.0%24.0%-1.3%
12M Excs Rtn-19.5%-42.9%-0.7%25.0%19.9%-8.4%-4.6%
3Y Excs Rtn-94.6%-83.5%-11.2%59.6%-1.2%28.4%-6.2%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Management of Diagnostic Imaging Centers9590898177
Manufacturing and Servicing of Medical Equipment99898
Inter-segment net revenues-1-1   
Total10399989086


Operating Income by Segment
$ Mil20252024202320222021
Management of Diagnostic Imaging Centers2321272120
Manufacturing and Servicing of Medical Equipment-7-6-5-3-6
Total1715221714


Assets by Segment
$ Mil20252024202320222021
Management of Diagnostic Imaging Centers184170169165150
Manufacturing and Servicing of Medical Equipment3031302530
Total214201199190180


Price Behavior

Price Behavior
Market Price$14.45 
Market Cap ($ Bil)0.1 
First Trading Date10/27/1993 
Distance from 52W High-11.9% 
   50 Days200 Days
DMA Price$14.77$14.58
DMA Trendindeterminatedown
Distance from DMA-2.2%-0.9%
 3M1YR
Volatility25.9%28.6%
Downside Capture35.6436.01
Upside Capture-1.0226.83
Correlation (SPY)3.3%11.0%
FONR Betas & Captures as of 11/30/2025

 1M2M3M6M1Y3Y
Beta0.290.060.130.100.180.37
Up Beta0.49-0.29-0.09-0.43-0.110.30
Down Beta0.020.250.230.210.310.39
Up Capture-38%-19%-21%11%16%8%
Bmk +ve Days12253873141426
Stock +ve Days7142052110340
Down Capture68%29%50%35%57%76%
Bmk -ve Days7162452107323
Stock -ve Days12274169132391

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
 Comparison of FONR With Other Asset Classes (Last 1Y)
 FONRSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-4.6%15.1%17.8%72.1%8.6%4.4%-8.2%
Annualized Volatility28.5%17.2%19.4%19.3%15.2%17.0%35.0%
Sharpe Ratio-0.170.650.722.700.340.09-0.08
Correlation With Other Assets 23.2%11.0%0.6%-6.6%17.0%1.2%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
 Comparison of FONR With Other Asset Classes (Last 5Y)
 FONRSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-4.7%8.4%14.7%18.7%11.5%4.6%30.8%
Annualized Volatility31.5%14.5%17.1%15.5%18.7%18.9%48.6%
Sharpe Ratio-0.100.400.700.970.500.160.57
Correlation With Other Assets 18.4%21.5%7.9%2.9%21.7%12.0%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
 Comparison of FONR With Other Asset Classes (Last 10Y)
 FONRSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-2.0%9.9%14.8%15.3%7.0%5.3%69.2%
Annualized Volatility37.0%16.6%18.0%14.7%17.6%20.8%55.8%
Sharpe Ratio0.060.490.710.860.320.220.90
Correlation With Other Assets 27.4%30.1%3.1%10.3%27.0%11.3%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date12152025
Short Interest: Shares Quantity8,981
Short Interest: % Change Since 1130202515.6%
Average Daily Volume33,928
Days-to-Cover Short Interest1
Basic Shares Quantity6,169,000
Short % of Basic Shares0.1%

Returns Analyses

SEC Filings

Expand for More
Report DateFiling DateFiling
93020251110202510-Q 9/30/2025
6302025922202510-K 6/30/2025
3312025515202510-Q 3/31/2025
12312024219202510-Q 12/31/2024
93020241112202410-Q 9/30/2024
6302024927202410-K 6/30/2024
3312024515202410-Q 3/31/2024
12312023214202410-Q 12/31/2023
93020231114202310-Q 9/30/2023
6302023928202310-K 6/30/2023
3312023515202310-Q 3/31/2023
12312022214202310-Q 12/31/2022
93020221114202210-Q 9/30/2022
6302022928202210-K 6/30/2022
3312022516202210-Q 3/31/2022
12312021214202210-Q 12/31/2021